Key points are not available for this paper at this time.
BACKGROUND: Long-acting depot antipsychotic medication is a widely used treatment for schizophrenia. AIMS: To synthesise relevant systematic Cochrane reviews. METHOD: The Cochrane Database was searched and summary data were extracted from randomised controlled clinical trials of depots. RESULTS: Standard dose depot v. placebo resulted in significantly less relapse but more movement disorders. Those on depots (v. oral drugs) showed more global change on one outcome measure; relapse and adverse effects showed no difference. Comparisons showed no convincing advantages for one depot over another. CONCLUSIONS: Depot antipsychotics are safe and effective. They may confer a small benefit over oral drugs on global outcome. Those for whom depots are most indicated may not be represented. Large studies are required to discern differences in relapse rates and long-term adverse effects, and data on satisfaction, quality of life and economics.
Adams et al. (Mon,) studied this question.